Drug Approval | December 04, 2024
Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005%
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
ALS patients experience neuroinflammation and rapid neurodegeneration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Subscribe To Our Newsletter & Stay Updated
